Patents Represented by Attorney Genentech, Inc.
-
Patent number: 8309300Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: GrantFiled: April 21, 2009Date of Patent: November 13, 2012Assignee: Genentech, Inc.Inventors: Jagath Reddy Junutula, Henry Lowman
-
Patent number: 8293735Abstract: Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110? isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: October 27, 2008Date of Patent: October 23, 2012Assignee: F. Hoffmann-La Roche AGInventors: Timothy Colin Hancox, Neil Anthony Pegg, Alan John Nadin, Stephen Price
-
Patent number: 8293736Abstract: The invention provides compounds having the general formula: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and n are defined herein, compositions including the compounds and method of using the compounds to treat a disease or disorder mediated by the p110 delta isoform of PI3 kinase selected from immune disorders, cancer, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.Type: GrantFiled: July 13, 2011Date of Patent: October 23, 2012Assignee: F. Hoffmann la Roche AGInventors: Jun Li, Brian Safina, Daniel P. Sutherlin, Zachary Sweeney
-
Patent number: 8263633Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: September 27, 2010Date of Patent: September 11, 2012Assignee: F. Hoffman-La Roche AGInventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
-
Patent number: 8168645Abstract: The invention relates generally to small molecules that mimic the biological activity of certain peptides and proteins, to compositions containing them and to their use. In particular, the invention relates to compounds of the general formula (I) that mimic the biological activity of BH3-only proteins and are capable of binding to and neutralizing pro-survival Bcl-2 proteins: wherein A1, A2, B1, B2, B3, X, Z, R1, R2, R3 and t are as described herein. The invention also relates to processes of preparing the benzenesulfonamide compounds that mimic portions of peptides and proteins, and to the use of such compounds in the regulation of cell death and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death.Type: GrantFiled: November 15, 2007Date of Patent: May 1, 2012Assignee: Genentech, Inc.Inventors: Jonathan Bayldon Baell, Guillaume Laurent Lessene, Brad Edmund Sleebs, Wayne J. Fairbrother, John A. Flygare, Michael F. T. Koehler
-
Patent number: 8163763Abstract: Disclosed are compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).Type: GrantFiled: July 31, 2009Date of Patent: April 24, 2012Assignee: Genentech, Inc.Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F. T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
-
Patent number: 8163518Abstract: Methods are presented for microwave assisted, enzymatic deglycosylation of proteins. The rate at which deglycosylation is achieved and without protein degradation facilitates rapid and accurate molecular weight determination by mass spectrometry.Type: GrantFiled: April 27, 2007Date of Patent: April 24, 2012Assignee: Genetech, Inc.Inventors: David P. Arnott, Jennie Lill, Wendy N. Sandoval, Richard L. Vandlen
-
Patent number: 8148106Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: February 8, 2011Date of Patent: April 3, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
-
Patent number: 8138152Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide.Type: GrantFiled: August 7, 2009Date of Patent: March 20, 2012Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Ellen H. Filvaroff, Diane Pennica
-
Patent number: 8071097Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: GrantFiled: March 21, 2008Date of Patent: December 6, 2011Assignee: Genentech, Inc.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
-
Patent number: 8063218Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein Q, X1, X2, Y, Z R1, R2, R3, R3?, R4, R4?, R5, R6, R6? and n are as described herein.Type: GrantFiled: December 14, 2007Date of Patent: November 22, 2011Assignee: Genentech, Inc.Inventor: Michael F. T. Koehler
-
Patent number: 7989595Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: June 14, 2006Date of Patent: August 2, 2011Assignee: Genentech, Inc.Inventors: Mark S. Dennis, William Mallet, Paul Polakis
-
Patent number: 7951916Abstract: The present invention is directed to novel polypeptides having homology to the IL-1-like family of proteins and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention, and methods for producing the polypeptides of the present invention.Type: GrantFiled: July 1, 2009Date of Patent: May 31, 2011Assignee: Genentech, Inc.Inventors: Audrey Goddard, Guohua James Pan
-
Patent number: 7947813Abstract: Methods are presented for isolating and purifying proteins by adding a polyelectrolyte to a cell culture fluid, such as a harvested cell culture fluid, and precipitating a protein-polyelectrolyte complex or a complex of impurities and the polyelectrolyte.Type: GrantFiled: January 10, 2008Date of Patent: May 24, 2011Assignee: Genentech, Inc.Inventors: Robert L. Fahrner, Jayme Franklin, Paul McDonald, Thanmaya Peram, Vikram Sisodiya, Corazon Victa
-
Patent number: 7855275Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: GrantFiled: March 6, 2009Date of Patent: December 21, 2010Assignee: Genentech, Inc.Inventors: Charles W. Eigenbrot, Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
-
Patent number: 7695928Abstract: The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators.Type: GrantFiled: April 9, 2007Date of Patent: April 13, 2010Assignee: Genentech, Inc.Inventors: Yingnan Zhang, Mike Costa, Sachdev S. Sidhu
-
Patent number: 7662926Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.Type: GrantFiled: January 18, 2007Date of Patent: February 16, 2010Assignee: Genentech, Inc.Inventors: Andrew C. Chan, Robert L. Shields, Lawren Wu
-
Patent number: 7632658Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.Type: GrantFiled: April 27, 2007Date of Patent: December 15, 2009Assignee: Genentech, Inc.Inventor: John C. Joly
-
Patent number: 7595399Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.Type: GrantFiled: February 4, 2004Date of Patent: September 29, 2009Assignee: Genentech, Inc.Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
-
Patent number: 7582445Abstract: Compositions of matter encoding or useful for expressing anti-interferon alpha antibodies are provided. Methods of using such compositions of matter for producing anti-interferon alpha antibodies are also provided.Type: GrantFiled: March 10, 2006Date of Patent: September 1, 2009Assignee: Genentech, Inc.Inventors: Chuntharapai Anan, Jin K. Kim, Leonard G. Presta, Timothy Stewart